Ownership Capital B.V. Sells 9,508 Shares of Insulet Co. (NASDAQ:PODD)

Ownership Capital B.V. lowered its holdings in Insulet Co. (NASDAQ:PODD - Free Report) by 3.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 277,624 shares of the medical instruments supplier's stock after selling 9,508 shares during the period. Insulet makes up about 1.3% of Ownership Capital B.V.'s holdings, making the stock its 21st biggest position. Ownership Capital B.V. owned about 0.40% of Insulet worth $60,239,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of PODD. Baillie Gifford & Co. bought a new stake in shares of Insulet in the fourth quarter valued at approximately $263,144,000. William Blair Investment Management LLC raised its position in shares of Insulet by 145.1% in the third quarter. William Blair Investment Management LLC now owns 732,923 shares of the medical instruments supplier's stock valued at $116,894,000 after purchasing an additional 433,884 shares during the period. Qube Research & Technologies Ltd raised its position in shares of Insulet by 227.3% in the third quarter. Qube Research & Technologies Ltd now owns 386,687 shares of the medical instruments supplier's stock valued at $61,673,000 after purchasing an additional 268,553 shares during the period. Westfield Capital Management Co. LP raised its position in shares of Insulet by 62.4% in the third quarter. Westfield Capital Management Co. LP now owns 637,261 shares of the medical instruments supplier's stock valued at $101,637,000 after purchasing an additional 244,922 shares during the period. Finally, Artisan Partners Limited Partnership bought a new stake in shares of Insulet in the third quarter valued at approximately $29,455,000.

Insider Buying and Selling at Insulet

In other Insulet news, Director Shacey Petrovic sold 11,609 shares of the stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $162.92, for a total transaction of $1,891,338.28. Following the completion of the sale, the director now owns 2,567 shares of the company's stock, valued at approximately $418,215.64. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.90% of the stock is currently owned by corporate insiders.

Insulet Price Performance

Shares of NASDAQ:PODD traded up $2.02 during trading on Friday, reaching $166.19. The company had a trading volume of 636,152 shares, compared to its average volume of 670,432. The company has a fifty day moving average of $171.51 and a two-hundred day moving average of $179.63. The stock has a market capitalization of $11.64 billion, a P/E ratio of 57.11, a price-to-earnings-growth ratio of 2.96 and a beta of 0.98. Insulet Co. has a 12 month low of $125.82 and a 12 month high of $335.91. The company has a current ratio of 3.51, a quick ratio of 2.62 and a debt-to-equity ratio of 1.86.

Insulet (NASDAQ:PODD - Get Free Report) last announced its quarterly earnings data on Thursday, February 22nd. The medical instruments supplier reported $1.40 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.67 by $0.73. Insulet had a net margin of 12.16% and a return on equity of 32.19%. The company had revenue of $509.80 million during the quarter, compared to analysts' expectations of $461.26 million. During the same quarter in the prior year, the company earned $0.55 EPS. The firm's revenue was up 37.9% on a year-over-year basis. Equities research analysts forecast that Insulet Co. will post 3.08 earnings per share for the current year.

Wall Street Analyst Weigh In

PODD has been the topic of several research reports. JPMorgan Chase & Co. boosted their price target on shares of Insulet from $190.00 to $225.00 and gave the company an "overweight" rating in a research report on Friday, February 23rd. Piper Sandler decreased their target price on shares of Insulet from $250.00 to $230.00 and set an "overweight" rating on the stock in a report on Friday, February 23rd. Stifel Nicolaus upped their target price on shares of Insulet from $163.00 to $208.00 and gave the stock a "hold" rating in a report on Monday, February 5th. Finally, Barclays decreased their target price on shares of Insulet from $214.00 to $213.00 and set an "equal weight" rating on the stock in a report on Monday, February 26th. Four research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $243.21.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.